Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma

Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma

BACKGROUND/AIMPredicting the prognosis of metastatic urothelial carcinoma (mUC) patients is needed for clinical decisions. We examined the value of a modified Glasgow prognostic score (mGPS) as a predictive marker for mUC patients. PATIENTS AND METHODSIn a multicenter study, 68 mUC patients received...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:In vivo (Athens) 2021-09, Vol.35 (5), p.2793-2800
Hauptverfasser: NAGAI, TAKASHI, NAIKI, TAKU, ISOBE, TERUKI, SUGIYAMA, YOSUKE, ETANI, TOSHIKI, IIDA, KEITARO, NOZAKI, SATOSHI, NODA, YUSUKE, SHIMIZU, NOBUHIKO, TASAKI, YOSHIHIKO, MIMURA, YOSHIHISA, BANNO, RIKA, KUBOTA, HIROKI, HAMAMOTO, SHUZO, KAWAI, NORIYASU, YASUI, TAKAHIRO
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND/AIMPredicting the prognosis of metastatic urothelial carcinoma (mUC) patients is needed for clinical decisions. We examined the value of a modified Glasgow prognostic score (mGPS) as a predictive marker for mUC patients. PATIENTS AND METHODSIn a multicenter study, 68 mUC patients received short hydration gemcitabine/cisplatin (shGC) and 74 received pembrolizumab (PEM). Patients were allocated according to mGPS. Progression-free (PFS) and cancer-specific (CSS) survival were examined. RESULTSHigher mGPS reflected poorer PFS and CSS in shGC (p=0.03, p
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.12565